Literature DB >> 25129475

Perioperative changes in pro and anticoagulant factors in prostate cancer patients undergoing laparoscopic and robotic radical prostatectomy with different anaesthetic techniques.

Maria Sofra1, Anna Antenucci2, Michele Gallucci3, Chiara Mandoj4, Rocco Papalia5, Claudia Claroni6, Ilaria Monteferrante7, Giulia Torregiani8, Valeria Gianaroli9, Isabella Sperduti10, Luigi Tomao11, Ester Forastiere12.   

Abstract

BACKGROUND: Laparoscopic prostatectomy (LRP) may activate clotting system influencing the risk of perioperative thrombosis in patients with prostate cancer. Moreover, different anaesthetic techniques can also modify coagulant factors. Thus, the aim of this study was to investigate the effects on pro- and anti-coagulant and fibrinolytic factors of two established types of anaesthesia in patients with prostate cancer undergoing elective LRP.
METHODS: 102 patients with primary prostate cancer, who underwent conventional LRP or robot-assisted laparoscopic prostatectomy (RALP), were studied and divided into 2 groups to receive total intravenous anesthesia with target-controlled infusion (TIVA-TCI) or balanced inhalation anaesthesia (BAL) prior to surgery. Before the induction of anaesthesia (T0), 1 hr (T1) and 24 hrs post-surgery (T2), some pro-coagulant factors, fibronolysis markers, p-selectin and haemostatic system inhibitors were evaluated.
RESULTS: Both TIVA-TCI and BAL patients showed a marked and significant increase in pro-coagulant factors and consequent reduction in haemostatic system inhibitors in the early post operative period (p ≤ 0.004 for each markers). Use of RALP showed a significant increase in prothrombotic markers as compared to LRP. In TIVA patients undergoing LRP, a significant reduction of p-selectin levels between T0 and T2 (p = 0.001) was observed as compared to BAL, suggesting a better protective effect on platelet activation of anaesthetic agents used for TIVA.
CONCLUSIONS: Both anaesthetic techniques significantly seem to increase the risk of thrombosis in prostate cancer patients undergoing LRP, mainly when the robotic device was utilized, encouraging the use of a peri-operative thromboembolic prophylaxis in these patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25129475      PMCID: PMC4431486          DOI: 10.1186/s13046-014-0063-z

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  43 in total

1.  Duplex ultrasound assessment of femoral venous flow during laparoscopic and open gastric bypass.

Authors:  N T Nguyen; M Cronan; S Braley; R Rivers; B M Wolfe
Journal:  Surg Endosc       Date:  2002-10-08       Impact factor: 4.584

Review 2.  Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease.

Authors:  J A Caprini; J I Arcelus; J J Reyna
Journal:  Semin Hematol       Date:  2001-04       Impact factor: 3.851

3.  Sevoflurane does not inhibit human platelet aggregation induced by thrombin.

Authors:  S Nozuchi; T Mizobe; H Aoki; N Hiramatsu; K Kageyama; F Amaya; K Uemura; T Fujimiya
Journal:  Anesthesiology       Date:  2000-01       Impact factor: 7.892

4.  Long-term coagulation changes after resection of thoracoabdominal malignancies.

Authors:  Robert M Van Haren; Evan J Valle; Chad M Thorson; Gerardo A Guarch; Jassin M Jouria; David M Andrews; Danny Sleeman; Joe U Levi; Alan S Livingstone; Kenneth G Proctor
Journal:  J Am Coll Surg       Date:  2014-01-15       Impact factor: 6.113

Review 5.  The hypercoagulable state of malignancy: pathogenesis and current debate.

Authors:  Graham J Caine; Paul S Stonelake; Gregory Y H Lip; Sean T Kehoe
Journal:  Neoplasia       Date:  2002 Nov-Dec       Impact factor: 5.715

6.  Sevoflurane inhibits human platelet aggregation and thromboxane A2 formation, possibly by suppression of cyclooxygenase activity.

Authors:  H Hirakata; F Ushikubi; H Toda; K Nakamura; S Sai; N Urabe; Y Hatano; S Narumiya; K Mori
Journal:  Anesthesiology       Date:  1996-12       Impact factor: 7.892

7.  Hemostatic alterations in patients with benign and malignant colorectal disease during major abdominal surgery.

Authors:  I I Modrau; L L Iversen; O O Thorlacius-Ussing
Journal:  Thromb Res       Date:  2001-12-01       Impact factor: 3.944

8.  Prognosis of cancers associated with venous thromboembolism.

Authors:  H T Sørensen; L Mellemkjaer; J H Olsen; J A Baron
Journal:  N Engl J Med       Date:  2000-12-21       Impact factor: 91.245

Review 9.  The effects of drugs used in anaesthesia on platelet membrane receptors and on platelet function.

Authors:  Sibylle A Kozek-Langenecker
Journal:  Curr Drug Targets       Date:  2002-06       Impact factor: 3.465

10.  Sevoflurane anesthesia attenuates adenosine diphosphate-induced P-selectin expression and platelet-leukocyte conjugate formation.

Authors:  Go-Shine Huang; Chi-Yuan Li; Ping-Ching Hsu; Chien-Sung Tsai; Tso-Chou Lin; Chih-Shung Wong
Journal:  Anesth Analg       Date:  2004-10       Impact factor: 5.108

View more
  2 in total

1.  PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience.

Authors:  Roberta Merola; Luigi Tomao; Anna Antenucci; Isabella Sperduti; Steno Sentinelli; Serena Masi; Chiara Mandoj; Giulia Orlandi; Rocco Papalia; Salvatore Guaglianone; Manuela Costantini; Giuseppe Cusumano; Giovanni Cigliana; Paolo Ascenzi; Michele Gallucci; Laura Conti
Journal:  J Exp Clin Cancer Res       Date:  2015-02-06

2.  MicroRNA-195 suppresses tumor cell proliferation and metastasis by directly targeting BCOX1 in prostate carcinoma.

Authors:  Jia Guo; Min Wang; Xiuheng Liu
Journal:  J Exp Clin Cancer Res       Date:  2015-09-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.